2023
DOI: 10.1016/j.dld.2023.01.006
|View full text |Cite
|
Sign up to set email alerts
|

Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: Who is the winner?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The phase 3 HIMALAYA trial showed the superiority of tremelimumab plus durvalumab (STRIDE regimen) [80,81] over sorafenib, and this regimen and durvalumab monotherapy were approved as first-line treatment in Japan in 2023. The STRIDE regimen is inferior to atezolizumab plus bevacizumab in terms of efficacy and safety according to phase 3 data and the recently published 3 network meta-analysis [82][83][84]. Therefore, STRIDE regimen is indicated for patients who are unsuitable for bevacizumab [85][86][87][88] (Fig.…”
Section: Treatment Of Advanced-stage Hcc (Bclc-c Stage)mentioning
confidence: 99%
“…The phase 3 HIMALAYA trial showed the superiority of tremelimumab plus durvalumab (STRIDE regimen) [80,81] over sorafenib, and this regimen and durvalumab monotherapy were approved as first-line treatment in Japan in 2023. The STRIDE regimen is inferior to atezolizumab plus bevacizumab in terms of efficacy and safety according to phase 3 data and the recently published 3 network meta-analysis [82][83][84]. Therefore, STRIDE regimen is indicated for patients who are unsuitable for bevacizumab [85][86][87][88] (Fig.…”
Section: Treatment Of Advanced-stage Hcc (Bclc-c Stage)mentioning
confidence: 99%